Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41
暂无分享,去创建一个
W. Weissenhorn | R. Weiss | F. Sallusto | A. Lanzavecchia | A. Hinz | D. Corti | Fabrizia Vanzetta | Chiara Silacci | Gloria Agatic | M. Seaman | G. Scarlatti | D. Lutje Hulsik | L. Mainetti | C. Sabin | Víctor Buzón
[1] Q. Sattentau,et al. International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II , 2009, PloS one.
[2] D. Burton,et al. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.
[3] D. Montefiori,et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates , 2010, Proceedings of the National Academy of Sciences.
[4] Felix Campelo,et al. Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions , 2010, PLoS pathogens.
[5] Q. Sattentau,et al. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.
[6] J. Condra,et al. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 , 2009, mAbs.
[7] J. Anglister,et al. Peptides in the treatment of AIDS. , 2009, Current opinion in structural biology.
[8] G. Melikyan,et al. HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.
[9] Q. Sattentau,et al. International Network for Comparison of HIV Neutralization Assays: The NeutNet Report , 2009, PloS one.
[10] J. Condra,et al. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. , 2008, AIDS research and human retroviruses.
[11] R. Ptak,et al. Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor , 2008, Journal of Biological Chemistry.
[12] A. Koné,et al. Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates , 2008, AIDS.
[13] D. Richman,et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. , 2008, Virology.
[14] S. Harrison. Viral membrane fusion , 2008, Nature Structural &Molecular Biology.
[15] J. Sodroski,et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.
[16] P. Gagnon,et al. Purification of IgM Monoclonal Antibodies : Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology , 2008 .
[17] C. Bewley,et al. A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains , 2007, Journal of Virology.
[18] F. Buonaguro,et al. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.
[19] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[20] Winfried Weissenhorn,et al. Virus membrane fusion , 2007, FEBS Letters.
[21] Kevin Harris,et al. Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery , 2007, J. Comput. Aided Mol. Des..
[22] H. Katinger,et al. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. , 2007, Biochemistry.
[23] D. Dimitrov,et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. , 2006, Biochemical and biophysical research communications.
[24] Feng Gao,et al. Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.
[25] Rebecca Hoh,et al. Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis , 2006, Journal of acquired immune deficiency syndromes.
[26] M. Luftig,et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody , 2006, Nature Structural &Molecular Biology.
[27] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[28] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[29] C. Bewley,et al. Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. , 2005, Journal of molecular biology.
[30] Gennaro Ciliberto,et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[32] Brett D. Welch,et al. Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.
[33] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[34] W. Weissenhorn,et al. Class I and class II viral fusion protein structures reveal similar principles in membrane fusion (Review) , 2004, Molecular membrane biology.
[35] Karsten Suhre,et al. ElNémo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement , 2004, Nucleic Acids Res..
[36] Shibo Jiang,et al. Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes , 2004, Journal of Virology.
[37] Michael Greenberg,et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.
[38] C. Bewley,et al. Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion* , 2003, Journal of Biological Chemistry.
[39] Samuel K Sia,et al. Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[40] Abraham Pinter,et al. Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.
[41] Michael S. Kay,et al. Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.
[42] G. Melikyan,et al. Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.
[43] P. S. Kim,et al. Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.
[44] Stuart L. Schreiber,et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.
[45] Anastassis Perrakis,et al. Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.
[46] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[47] P. S. Kim,et al. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. , 1998, Journal of molecular biology.
[48] Eric Hunter,et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.
[49] A. Gronenborn,et al. Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.
[50] C. Weiss,et al. Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.
[51] C. Weiss,et al. Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.
[52] T. Matthews,et al. Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.
[53] S. Durell,et al. Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.
[54] E. Fenyö,et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.
[55] A. Trkola,et al. Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.
[56] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[57] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[58] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[59] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[60] J. Albert,et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.
[61] T. Oas,et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[62] Luc Montagnier,et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV , 1984, Nature.
[63] M. Greaves,et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.